Kadence Bio is a clinical stage therapeutics company whose mission is to develop innovative therapeutics to address critical unmet needs in sexual and mental health. We are developing a first-in-class treatment for premature ejaculation to bridge the 'intimacy gap' (~3x difference in average time to orgasm between men and women). There is currently no treatment approved by the FDA to treat the condition, which affects up to 20% of men and their partners. Our Board includes the global CMO of GSK.